-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2022-501599-25-00
5
2024-03-19
juvenile idiopathic arthritis
-
2022-502783-21-00
5
2024-02-20
B-Cell Non-Hodgkin's Lymphoma
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma
-
2022-501551-90-00
10
2023-12-13
Prostate cancer
-
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-522029-37-00
5
2026-02-27
Large B-cell Lymphoma
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-517261-16-00
9
2025-12-05
Advanced solid tumors
-
2025-521153-16-00
5
2025-12-05
bacterial sexually transmitted infections
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2025-520744-14-00
6
2025-10-01
Critically ill patients
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi